<DOC>
	<DOCNO>NCT01925599</DOCNO>
	<brief_summary>The BAP1 trial examine blood patient diagnose choroidal nevi uveal melanoma germline BAP1 mutation genetic marker associate develop malignancy well additional sequence uveal melanoma genome .</brief_summary>
	<brief_title>BAP1 Testing Instance Choroidal Nevi Uveal Melanoma</brief_title>
	<detailed_description>A germline BAP1 mutation predisposes person develop uveal melanoma cancer . If mutation discover , change potential approach manage nevus . In presence know genomic change associate aggressive disease , close follow aggressive treatment could preserve patient 's vision prevent micrometastatic spread . This new screening technique able extend length quality life patient frequent targeted cancer screen .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Nevus</mesh_term>
	<criteria>person choroidal nevi Willingness provide sign informed consent Age &gt; 18 year Diagnosis choroidal nevi uveal melanoma Threre exclusionary criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Nevus</keyword>
	<keyword>Choroidal Melanoma</keyword>
	<keyword>BAP1 mutation</keyword>
</DOC>